Sustaining T-cells is key to better cancer treatment. Leveraging our proprietary MHC-SNAP technology, we can identify a broader spectrum of immunologically relevant surface peptides including non-canonical T cell epitopes overlooked by AI and mass spectrometry to build new approaches for immune related CD8 T Cell mediated disease including cancer and infectious diseases. Our first product is a peptide vaccine for KRAS G12D and G12V driven lung cancer, with potential to boost CD8 T cells.